Table 1 Heavy peptide standard sequences for quantification of phosphorylated and non-phosphorylated ERK1 and ERK2 by mass spectrometry

From: MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Speciesa

Peptideb

m/z

charge

t start [min]

t stop [min]

Max injection time [ms]

AGC target

ERK1_L_NP

GQPFDVGPR

486.7485

2

0

19

250

100,000

ERK1_H_NP

GQPFDVGPRH

491.7527

2

0

19

250

100,000

ERK2_L_NP

GQVFDVGPR

487.7563

2

0

19

250

100,000

ERK2_H_NP

GQVFDVGPRH

492.7605

2

0

19

250

100,000

ERK1_L_P

IADPEHDHTGFLpTEpYVATR

777.9943

3

19

32

500

50,000

ERK1_H_P

IADPEHDHTGFLpTEpYVATRH

781.3304

3

19

32

100

50,000

ERK2_L_P

VADPDHDHTGFLpTEpYVATR

768.6505

3

19

32

500

50,000

ERK2_H_P

VADPDHDHTGFLpTEpYVATRH

771.9866

3

19

32

100

50,000

  1. AGC, automatic gain control
  2. a Peptide features: L light, H heavy, NP non-phospho, P phospho
  3. b Peptide sequences: pT phospho-threonine, pY phospho-tyrosine, RH heavy isotope arginine